Ubs Asset Management Americas Inc Rhythm Pharmaceuticals, Inc. Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 218,544 shares of RYTM stock, worth $11.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
218,544
Previous 225,373
3.03%
Holding current value
$11.6 Million
Previous $11.8 Million
3.46%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding RYTM
# of Institutions
215Shares Held
64.4MCall Options Held
445KPut Options Held
26.6K-
Black Rock Inc. New York, NY6.74MShares$357 Million0.01% of portfolio
-
Primecap Management CO Pasadena, CA6.57MShares$348 Million0.29% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.08MShares$322 Million5.51% of portfolio
-
Baker Bros. Advisors LP New York, NY6.08MShares$322 Million3.77% of portfolio
-
Perceptive Advisors LLC New York, NY3.68MShares$195 Million6.86% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $2.95B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...